Neurocrine Biosciences, Xenon Pharmaceuticals Provide Regulatory Update On Ongoing Collaboration To Develop First-In-Class Treatment For Epilepsy; Says FDA Grants Rare Pediatric Disease Designation For NBI-921352 For Treatment Of SCN8A-DEE